Trontinemab (RG6102) is a brain-penetrant, anti-amyloid, bispecific and humanizedized IgG1-kappa antibody, targeting to Abeta plaques and transferrin receptor 1 (TFR1). Trontinemab binds to fibrillar Abeta as well as Abeta plaques triggering plaque clearance by engaging immune cells on Alzheimer disease (AD) brain sections. Trontinemab also shows specific affinity to cynomolgus and human TFR1[1][2][3][4].
Molecular Weight:
(194.25 kDa)
Purity:
99.90
CAS Number:
[2568868-35-7]
Target:
Amyloid-beta
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
